Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
biotech · Blepharitis · Meibomian Gland Dysfunction · TARS
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
15440 Laguna Canyon Rd, Irvine, California 92618, US HQ
2017 Founded
403 Employees
Public company Type
TARS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 15440 Laguna Canyon Rd, Irvine, California 92618, US
- Founded
- 2017
- Employees
- 403
- Programs
- 14
- Drugs
- 10
- Patents
- 9
Tarsus Pharmaceuticals pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tarsus Pharmaceuticals drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Ectoparasiticide.
- Mechanism
- Ectoparasiticide
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Tarsus Pharmaceuticals in public FDA and regional records.